1.Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.
Gianluigi TAVERNA ; Fabio GRIZZI ; Piergiuseppe COLOMBO ; Mauro SEVESO ; Guido GIUSTI ; Silvia PROIETTI ; Girolamo FIORINI ; Giovanni LUGHEZZANI ; Paolo CASALE ; Nicolo BUFFI ; Massimo LAZZARI ; Giorgio GUAZZONI
Korean Journal of Urology 2015;56(6):435-442
PURPOSE: Prostate cancer is the most frequent cancer in men in Europe. A major focus in urology is the identification of new biomarkers with improved accuracy in patients with low-risk prostate cancer. Here, we evaluated two-dimensional neovascular complexity in prostate tumor and nontumor biopsy cores by use of a computer-aided image analysis system and assessed the correlations between the results and selected clinical and pathological parameters of prostate carcinoma. MATERIALS AND METHODS: A total of 280 prostate biopsy sections from a homogeneous series of 70 patients with low-risk prostate cancer (Gleason score 3+3, prostate-specific antigen [PSA]<10 ng/mL, and clinical stage T1c) who underwent systematic biopsy sampling and subsequent radical prostatectomy were analyzed. For each biopsy, 2-microm sections were treated with CD34 antibodies and were digitized by using an image analysis system that automatically estimates the surface fractal dimension. RESULTS: Our results showed that biopsy sections without cancer were significantly more vascularized than were tumors. No correlations were found between the vascular surface fractal dimension and patient's age, PSA and free-to-total PSA ratios, pathological stage, Gleason score, tumor volume, vascular invasion, capsular penetration, surgical margins, and biochemical recurrence. CONCLUSIONS: The value of angiogenesis in prostate cancer is still controversial. Our findings suggest that low-risk prostate cancer tissues are less vascularized than are nontumor tissues. Further studies are necessary to understand whether angiogenesis is a hallmark of intermediate- and high-risk prostate cancer.
Adult
;
Aged
;
Biopsy, Needle
;
Fractals
;
Humans
;
Image Processing, Computer-Assisted/methods
;
Kallikreins/blood
;
Male
;
Middle Aged
;
Neoplasm Grading
;
Neoplasm Staging
;
Neovascularization, Pathologic/*pathology
;
Prostate/*blood supply
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*blood supply/pathology/surgery
;
Retrospective Studies
2.Low-Dose Acetazolamide in the Treatment of Premenstrual Dysphoric Disorder: A Case Series.
Gabriele SANI ; Georgios D KOTZALIDIS ; Isabella PANACCIONE ; Alessio SIMONETTI ; Lavinia DE CHIARA ; Antonio DEL CASALE ; Elisa AMBROSI ; Flavia NAPOLETANO ; Delfina JANIRI ; Emanuela DANESE ; Nicoletta GIRARDI ; Chiara RAPINESI ; Daniele SERATA ; Giovanni MANFREDI ; Alexia E KOUKOPOULOS ; Gloria ANGELETTI ; Ferdinando NICOLETTI ; Paolo GIRARDI
Psychiatry Investigation 2014;11(1):95-101
The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.
Acetazolamide*
;
Anxiety Disorders
;
Carbonic Anhydrases
;
Comorbidity
;
Female
;
Follow-Up Studies
;
Humans
;
Mood Disorders